Abstract: Objective: To analyze the clinical characteristics, treatment and prognosis of patients with diffuse large B cell lymphoma (DLBCL) with intermediate-high and high risk. Methods:Forty-two patients with diffuse large B cell lympho-ma classified into intermediate-high and high risk were collected, along with the IPI score and Ann Arbor staging. The cura-tive effects of chemotherapy and hematopoietic stem cell transplantation were analyzed. Results: According to the interna -tional prognostic index (IPI), there were 25cases (59.52% ) with intermediate-high risk and 17cases (40.48% ) with high risk. According to Ann Arbor staging, there were 2 phase II cases (4.76%),29phase III cases ( 69.05%) and11phase IV cases (26.19%). Ten cases (23.81%) were accompanied with bone marrow invasion. Of the total cases,5 were diagnosed as lymphosarcoma cell leukemia; 38cases (90.48%) had an increase in LDH level and the maximum exceeded10000 U/L; 35cases (83.33%) had B symptom. The response rate (RR) for the whole group was 71.43%, the complete remission (CR) rate was 59.52% (25cases), the partial remission (PR) rate was 11.90% (5 cases), the stable disease rate was2.38% (1 case) and the death rate was 26.19% (11cases). The 4-year survival rate was 73.81%. The complete remission rate was 72.73% in the hematopoietic stem cell transplantation group and 54.84% in the chemotherapy group. The meta-life span was 35.38months for patients in the hematopoietic stem cell transplantation group and 29.25months for patients in chemo -therapy group. Multivariate analysis showed that IPI score, clinical stage, therapy modality and hematopoietic stem cell transplantation were significant factors for prognosis. Conclusion:The major treatment for diffuse large B cell lymphoma is standard chemotherapy. Hematopoietic stem cell transplantation is the best choice for treating patients with diffuse large B cell lymphoma.